Advisory Committee on Immunization Practices (ACIP) Meeting
Last week, the ACIP met to discuss the latest vaccine and vaccine-preventable disease research and make vaccine recommendations. ACIP reaffirmed the recommendation that all persons 6 months and older get an annual influenza vaccine (first issued in 2010), and extended the interim recommendation (issued for 2016-17) that the nasal spray vaccine (LAIV) not be used during the 2017-18 season. These recommendations must now be approved by the CDC Director and will be published in final form in August.
Frequently Asked Flu Questions 2017-2018 Influenza Season
Information for 2017-2018
Getting an annual flu vaccine is the first and best way to protect yourself and your family from the flu. Flu vaccination can reduce flu illnesses, doctors’ visits, and missed work and school due to flu, as well as prevent flu-related hospitalizations. The more people who get vaccinated, the more people will be protected from flu, including older people, very young children, pregnant women and people with certain health conditions who are more vulnerable to serious flu complications. This page summarizes information for the 2017-2018 flu season.
What viruses will the 2017-2018 flu vaccines protect against?
There are many flu viruses and they are constantly changing. The composition of U.S. flu vaccines is reviewed annually and updated to match circulating flu viruses. Flu vaccines protect against the three or four viruses that research suggests will be most common. For 2017-2018, three-component vaccines are recommended to contain:
- an A/Michigan/45/2015 (H1N1)pdm09-like virus
- an A/Hong Kong/4801/2014 (H3N2)-like virus
- a B/Brisbane/60/2008-like (B/Victoria lineage) virus
Four-component vaccines, which protect against a second lineage of B viruses, are recommended to be produced using the same viruses recommended for the trivalent vaccines, as well as a B/Phuket/3073/2013-like (B/Yamagata lineage) virus.